UCB's Cimzia alleviates Crohn's Disease symptoms in phase-3 trial

By Angela McDaniels

Seattle, Oct. 31 - UCB said phase-3 research presented at the annual meeting of the American College of Gastroenterology found that a 400 milligram injection of UCB's Cimzia every four weeks was effective in controlling symptoms of Crohn's Disease.

William J. Sandborn, professor of medicine at the Mayo Clinic College of Medicine in Rochester, Minn., led the study, which found that 48% of patients receiving Cimzia maintenance therapy were in clinical remission at week 26, compared to 29% of patients given a placebo.

UCB said a regulatory submission for the treatment of Crohn's Disease is planned in the United States during the first quarter of 2006.

Cimzia is a biologic agent that inhibits a protein involved in the gastro-intestinal inflammation process found in people with Crohn's Disease, the company said.

UCB is pharmaceutical company based in Brussels that develops products in the fields of central nervous system disorders, allergy and respiratory diseases, immune and inflammatory disorders and oncology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.